Toleranzia AB (TOL.ST)
SEK 0.44
(5.77%)
SEK 0.44
(5.77%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 850 Thousand SEK | 0.0% |
| 2022 | 850 Thousand SEK | 0.0% |
| 2021 | 850 Thousand SEK | 0.0% |
| 2020 | 850 Thousand SEK | -0.61% |
| 2019 | 855.2 Thousand SEK | 0.0% |
| 2018 | 855.2 Thousand SEK | -12.75% |
| 2017 | 980.2 Thousand SEK | -5.99% |
| 2016 | 1.04 Million SEK | -5.12% |
| 2015 | 1.09 Million SEK | 29.29% |
| 2014 | 850 Thousand SEK | 112.5% |
| 2013 | 400 Thousand SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - SEK | -100.0% |
| 2024 Q3 | 7.5 Million SEK | 0.0% |
| 2024 Q2 | - SEK | 0.0% |
| 2023 Q2 | 850 Thousand SEK | 0.0% |
| 2023 Q1 | 850 Thousand SEK | 0.0% |
| 2023 FY | 850 Thousand SEK | 0.0% |
| 2023 Q4 | 850 Thousand SEK | 0.0% |
| 2023 Q3 | 850 Thousand SEK | 0.0% |
| 2022 Q3 | 850 Thousand SEK | 0.0% |
| 2022 FY | 850 Thousand SEK | 0.0% |
| 2022 Q4 | 850 Thousand SEK | 0.0% |
| 2022 Q1 | 850 Thousand SEK | 0.0% |
| 2022 Q2 | 850 Thousand SEK | 0.0% |
| 2021 Q1 | 850 Thousand SEK | 0.0% |
| 2021 Q4 | 850 Thousand SEK | 0.0% |
| 2021 Q3 | 850 Thousand SEK | 0.0% |
| 2021 FY | 850 Thousand SEK | 0.0% |
| 2021 Q2 | 850 Thousand SEK | 0.0% |
| 2020 Q1 | 850 Thousand SEK | -0.61% |
| 2020 Q2 | 850 Thousand SEK | 0.0% |
| 2020 Q3 | 850 Thousand SEK | 0.0% |
| 2020 Q4 | 850 Thousand SEK | 0.0% |
| 2020 FY | 850 Thousand SEK | -0.61% |
| 2019 Q2 | 855.2 Thousand SEK | 0.61% |
| 2019 Q1 | 850 Thousand SEK | -0.61% |
| 2019 Q4 | 855.2 Thousand SEK | 0.0% |
| 2019 Q3 | 855.2 Thousand SEK | 0.0% |
| 2019 FY | 855.2 Thousand SEK | 0.0% |
| 2018 Q2 | 948.05 Thousand SEK | -1.62% |
| 2018 Q4 | 855.2 Thousand SEK | -8.28% |
| 2018 FY | 855.2 Thousand SEK | -12.75% |
| 2018 Q3 | 932.42 Thousand SEK | -1.65% |
| 2018 Q1 | 963.67 Thousand SEK | -1.69% |
| 2017 Q1 | 1.02 Million SEK | -1.5% |
| 2017 FY | 980.2 Thousand SEK | -5.99% |
| 2017 Q2 | 1.01 Million SEK | -1.52% |
| 2017 Q4 | 980.2 Thousand SEK | -1.57% |
| 2017 Q3 | 995.83 Thousand SEK | -1.54% |
| 2016 Q1 | 1.08 Million SEK | -0.86% |
| 2016 FY | 1.04 Million SEK | -5.12% |
| 2016 Q3 | 1.05 Million SEK | -1.45% |
| 2016 Q2 | 1.07 Million SEK | -1.43% |
| 2016 Q4 | 1.04 Million SEK | -1.48% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 FY | 1.09 Million SEK | 29.29% |
| 2015 Q4 | 1.09 Million SEK | 0.0% |
| 2014 FY | 850 Thousand SEK | 112.5% |
| 2014 Q4 | 850 Thousand SEK | 0.0% |
| 2013 FY | 400 Thousand SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 26.35 Million SEK | 96.775% |
| Enzymatica AB (publ) | 24.88 Million SEK | 96.584% |
| Enorama Pharma AB (publ) | 303 Thousand SEK | -180.528% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | 3.46 Million SEK | 75.483% |
| Nanexa AB (publ) | 2.08 Million SEK | 59.272% |
| Newbury Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 448.4 Million SEK | 99.81% |
| Probi AB (publ) | 38.21 Million SEK | 97.776% |
| Swedencare AB (publ) | 1.44 Billion SEK | 99.941% |
| Swedish Orphan Biovitrum AB (publ) | 11.35 Billion SEK | 99.993% |
| Vivesto AB | 5.18 Million SEK | 83.594% |